Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma
NCT05012098Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2022
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in olfactory neuroblastoma (ONB), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 28 days. Started Jun 2022; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
olfactory neuroblastoma (ONB)
Beyond the preview
Go deeper on NCT05012098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05012098.